VERTEX PHARMACEUTICALS INC
Aktie · US92532F1003 · VRTX · 882807 (XNAS)
450,50 USD
06.06.2025 20:40
Aktuelle Kurse von VERTEX PHARMACEUTICALS INC
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung |
---|---|---|---|---|---|
![]() NASDAQ |
VRTX
|
USD
|
06.06.2025 20:40
|
450,50 USD
| 443,82 USD
+1,51 %
|
![]() XETRA |
VX1.DE
|
EUR
|
06.06.2025 15:35
|
393,10 EUR
| 389,55 EUR
+0,91 %
|
![]() London |
0QZU.L
|
USD
|
06.06.2025 15:14
|
448,32 USD
| 443,82 USD
+1,01 %
|
Performance
Jour | Semaine | Mois | 3 mois | 6 mois | 1 an | 5 ans |
---|---|---|---|---|---|---|
0,00 % | 1,91 % | 0,10 % | -7,25 % | -2,87 % | -6,88 % | 69,56 % |
Profil de l'entreprise pour VERTEX PHARMACEUTICALS INC Action
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Fonds investis
Les fonds suivants ont investi dans : VERTEX PHARMACEUTICALS INC investi :
Fonds | Vol. en millions 1.695,46 | Part (%) 3,98 % |
Fonds | Vol. en millions 1.478,90 | Part (%) 1,14 % |
Fonds | Vol. en millions 645,34 | Part (%) 1,14 % |
Fonds | Vol. en millions 19.976,49 | Part (%) 1,14 % |
Fonds | Vol. en millions 1.137,69 | Part (%) 1,10 % |
Données de l'entreprise
Nom VERTEX PHARMACEUTICALS INC
Société Vertex Pharmaceuticals Incorporated
Symbole VRTX
Site web
https://www.vrtx.com
Marché d'origine
NASDAQ

WKN 882807
ISIN US92532F1003
Type de titre Action
Secteur Healthcare
Industrie Biotechnology
PDG Dr. Reshma Kewalramani FASN, M.D.
Capitalisation boursière 110 Mrd.
Pays États-Unis d'Amérique
Devise USD
Employés 6,1 T
Adresse 50 Northern Avenue, 02210 Boston
Date d'introduction en bourse 2007-12-28
Fractionnements d'actions
Date | Fractionnement |
---|---|
24.08.2000 | 2:1 |
Symboles boursiers
Nom | Symbole |
---|---|
Frankfurt | VX1.F |
London | 0QZU.L |
NASDAQ | VRTX |
XETRA | VX1.DE |
Autres actions
Les investisseurs qui détiennent VERTEX PHARMACEUTICALS INC ont également les actions suivantes dans leur portefeuille :
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles.
Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.